No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
DVAX240816P10000
- 0.30
- -0.05-14.29%
15min DelayTrading Jul 22 14:36 ET
0.35High0.30Low
0.35Open0.35Pre Close58 Volume4 Open Interest10.00Strike Price2.03KTurnover53.49%IV10.19%PremiumAug 16, 2024Expiry Date0.00Intrinsic Value100Multiplier25DDays to Expiry0.30Extrinsic Value100Contract SizeAmericanOptions Type-0.2538Delta0.2099Gamma43.20Leverage Ratio-0.0093Theta-0.0019Rho-10.96Eff Leverage0.0091Vega
Intraday
- 5D
- Daily
News
Dynavax Technologies (NASDAQ:DVAX) Has Debt But No Earnings; Should You Worry?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the permanent loss of capital.' It's only natural to consider a company's balance sheet
H.C. Wainwright Maintains Dynavax Technologies(DVAX.US) With Buy Rating, Maintains Target Price $29
H.C. Wainwright analyst Edward White maintains $Dynavax Technologies(DVAX.US)$ with a buy rating, and maintains the target price at $29.According to TipRanks data, the analyst has a success rate of 28
Dynavax Reports First Participant Dosed in Shingles Vaccine Trial
Dynavax Technologies (DVAX) said late Thursday the first participant has been dosed in its phase 1/2 study of its vaccine candidate Z-1018 to prevent shingles, a disease caused by the varicella-zoster
Express News | Dynavax Initiates Phase 1/2 Study Of Novel Shingles Vaccine Program Evaluating Safety, Tolerability And Immunogenicity Of Z-1018
Express News | Dynavax Technologies Corp: Anticipates Reporting Top Line Immunogenicity and Safety Data in Second Half of 2025
Express News | Dynavax Initiates Phase 1/2 Study of Novel Shingles Vaccine Program
Comments
📣 2 PDUFAs left in May!
🗓️ Last week’s PDUFAs:
$Amgen(AMGN.US$ : Approved 5/16 🎉
⇒ Imdelltra (Tarlatamab-dlle)
‣ extensive-stage SCLC
‣ PDUFA date: 6/12/24 (BLA)
$Bristol-Myers Squibb(BMY.US$ : Approved 5/15 🎉
⇒ Breyanzi®
‣ Follicular lymphoma
‣ PDUFA date: 5/23/24 (sBLAs)
$Dynavax Technologies(DVAX.US$ : CRL 5/14 🙁
⚠️ insufficient data
⇒ Heplisav-B
‣ vaccination of adults on hemodialysis
‣ PDUFA date: 5/13/24 (sBLA)
$Ascendis Pharma A/S(ASND.US$ : Review extended to 8/14/24 🤔
⇒ YORV...
🗓️ Last week’s PDUFAs:
$Amgen(AMGN.US$ : Approved 5/16 🎉
⇒ Imdelltra (Tarlatamab-dlle)
‣ extensive-stage SCLC
‣ PDUFA date: 6/12/24 (BLA)
$Bristol-Myers Squibb(BMY.US$ : Approved 5/15 🎉
⇒ Breyanzi®
‣ Follicular lymphoma
‣ PDUFA date: 5/23/24 (sBLAs)
$Dynavax Technologies(DVAX.US$ : CRL 5/14 🙁
⚠️ insufficient data
⇒ Heplisav-B
‣ vaccination of adults on hemodialysis
‣ PDUFA date: 5/13/24 (sBLA)
$Ascendis Pharma A/S(ASND.US$ : Review extended to 8/14/24 🤔
⇒ YORV...
10
$Dynavax Technologies(DVAX.US$ Reuters· 1 min ago
Dynavax: Crl States Application Did Not Provide Sufficient Data to Support Full Evaluation of Effectiveness or Safety of 4-Dose Regimen of Heplisav-B
Dynavax: Crl States Application Did Not Provide Sufficient Data to Support Full Evaluation of Effectiveness or Safety of 4-Dose Regimen of Heplisav-B
1
See summary 👇
📣 4 PDUFAs upcoming in May:
$Dynavax Technologies(DVAX.US$ : 🤔
⇒ Heplisav-B
‣ vaccination of adults on hemodialysis
‣ PDUFA date: 5/13/24 (sBLA)
$Ascendis Pharma A/S(ASND.US$ : 🤔
⇒ YORVIPATH®
‣ hypoparathyroidism
‣ PDUFA date: 5/14/24 (NDA)
$Bristol-Myers Squibb(BMY.US$ : 🤔
⇒ Breyanzi®
‣ PDUFA dates: (sBLAs)
‣‣ 5/23/24 (r/r follicular lymphoma)
‣‣ 5/31/24 (r/r mantle cell lymphoma)
🗓️ Last week’s PDUFAs:
$X4 Pharmaceuticals(XFOR.US$ : Approved 4/29 🎉
⇨ XOLREMDI (mavorixafor)
‣ WHI...
📣 4 PDUFAs upcoming in May:
$Dynavax Technologies(DVAX.US$ : 🤔
⇒ Heplisav-B
‣ vaccination of adults on hemodialysis
‣ PDUFA date: 5/13/24 (sBLA)
$Ascendis Pharma A/S(ASND.US$ : 🤔
⇒ YORVIPATH®
‣ hypoparathyroidism
‣ PDUFA date: 5/14/24 (NDA)
$Bristol-Myers Squibb(BMY.US$ : 🤔
⇒ Breyanzi®
‣ PDUFA dates: (sBLAs)
‣‣ 5/23/24 (r/r follicular lymphoma)
‣‣ 5/31/24 (r/r mantle cell lymphoma)
🗓️ Last week’s PDUFAs:
$X4 Pharmaceuticals(XFOR.US$ : Approved 4/29 🎉
⇨ XOLREMDI (mavorixafor)
‣ WHI...
7
2
The FDA PDUFA Calendar is a chronological calendar of PDUFA target dates as well as Advisory meetings (ADCOMM). PDUFA target dates are dates by which the FDA aims to deliver their decision regarding an NDA or BLA filing. These decisions can however come before the PDUFA target date.
$Pfizer(PFE.US$ $Dynavax Technologies(DVAX.US$ $Sandstorm Gold(SAND.US$ $Bristol-Myers Squibb(BMY.US$ $SPDR S&P Biotech ETF(XBI.US$
$Pfizer(PFE.US$ $Dynavax Technologies(DVAX.US$ $Sandstorm Gold(SAND.US$ $Bristol-Myers Squibb(BMY.US$ $SPDR S&P Biotech ETF(XBI.US$
10
1
Read more